Free Trial
NASDAQ:GOSS

Gossamer Bio Q2 2025 Earnings Report

Gossamer Bio logo
$1.98 -0.18 (-8.33%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$1.70 -0.29 (-14.39%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Gossamer Bio Revenue Results

Actual Revenue
$11.49 million
Expected Revenue
$4.12 million
Beat/Miss
Beat by +$7.37 million
YoY Revenue Growth
N/A

Gossamer Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Gossamer Bio's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gossamer Bio Earnings Headlines

FY2025 EPS Estimates for Gossamer Bio Increased by Analyst
Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
See More Gossamer Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email.

About Gossamer Bio

Gossamer Bio (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

View Gossamer Bio Profile

More Earnings Resources from MarketBeat